CSS
CRSP icon

Cubist Systematic Strategies’s CRISPR Therapeutics CRSP Stock Holding History

Cubist Systematic Strategies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$726K Buy
+11,200
New +$643K ﹤0.01% 2102
2023
Q3 		– Sell
-4,700
Closed -$264K – 3435
2023
Q2 		$264K Sell
4,700
-2,000
-30% -$113K ﹤0.01% 2689
2023
Q1 		$303K Buy
+6,700
New +$325K ﹤0.01% 2990

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Cubist Systematic Strategies's CRSP Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 33,195 shares — an estimated $2.08M sold.

Cubist Systematic Strategies first reported a position in CRSP in Q3 2018 and held it in 20 quarters. The position peaked at $7.4M in Q4 2020. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Cubist Systematic Strategies reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 33,195 CRISPR Therapeutics shares in Q1 2024, an estimated $2.08M.
  • Cubist Systematic Strategies first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 20 quarters.
  • Cubist Systematic Strategies's CRISPR Therapeutics position peaked at $7.4M in Q4 2020.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.